Description

Chronically psychotic patients in the maintenance phase of treatment are frequently medication non-adherent and have inadequate community supports; relapse is common.  This learning program will teach participants to identify the multiple barriers to successful maintenance treatment and recovery.  Participants will also learn specific strategies to address these obstacles and maximize the long-term health and stability of chronically psychotic patients.

Learning Objectives

Perform an appropriate baseline assessment of patients to identify risk factors for developing metabolic abnormalities, institute a periodic monitoring regimen to assess patients for antipsychotic-induced metabolic side effects.

Faculty

David C. Henderson, MD
Director, Schizophrenia Diabetes and Weight Reduction Research Program
Massachusetts General Hospital
Associate Professor of Psychiatry
Harvard Medical School

Accreditation

Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of McLean Hospital, Massachusetts General Hospital Academy and Reed Medical Education. McLean Hospital is accredited by the ACCME to provide continuing medical education (CME) for physicians.

Credit Designation
McLean Hospital designates this continuing medical educational activity for a maximum of 1 AMA PRA Category 1 Credits(TM). Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty and Provider Disclosure
It is the policy of McLean Hospital that faculty and providers disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). McLean Hospital has established policies in place that identify and resolve all conflicts of interest prior to this educational activity.

Supporters:  
Our evidence-based curriculum is supported by educational grants from Pfizer and Janssen.

Supporters

Our evidence-based curriculum is supported by educational grants from Pfizer and Janssen.

• 
  
•